Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-05-02
2006-05-02
Crouch, Deborah (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100
Reexamination Certificate
active
07037903
ABSTRACT:
A method for using thymosin β-10 for cancer treatment by expressing thymosin β-10 in solid malignant tumor cells. More precisely, the present invention relates to a cancer treatment method wherein thymosin β-10 is expressed in solid malignant tumor cells by infecting adenovirus including thymosin β-10. The gene therapy for cancer using thymosin β-10 of the present invention is very effective for the treatment of ovarian cancer, cervical cancer, stomach cancer and lung cancer.
REFERENCES:
patent: 2002/0168771 (2002-11-01), Gamerman
Verma et al. (1997) Gene Therapy-promises, problems and prospects. Nature. 389,:239-242.
Marshall (1995)Gene Therapy's Growing Pains. Science. 269:1050-1055.
Orkin et al. (1995) Report and recommendations of the panel to assess the NIH investment in research on gene therapy,1-44.
Arnold et al., (2002) Chromosome 8 genetic analysis and phenotypic characterizaton of 21 ovarian cancer cell lines. Cancer Genetics and Cytogeneitcs139:109-114.
Kammerer et al. (2003) Expression of Tumor Markers on Breast and Ovarian Cancer Cell Lines. Anticancer Research 23:1051-5.
Jung et al. (2002) CT and MR Imaging of Ovarian Tumors with Emphasis on Differential Diagnosis. Radiographics, 22:1305-25.
Huard (1995) The Route of administration is a major determinant of the transduction efficeiency of rat tissues by adenoviral recombinants. Gene Ther. 2:107-15.
McCluskie et al. (1999) Route and administration of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates. Molecular Medicien 5::287-300.
A.K. Hall, “Thymosin Beta-10 Accelerates Apoptosis,” Cell and Mol. Bio. Res., 1995, 41(3): 167-180.
V.T. Nachmias, “Small Actin-Binding Proteins: the β-Thymosin Family,” Current Opinion in Cell Biology, 1993, 5: 56-62.
E. Vasile et al., “Differential Expression of Thymosin β-10 by Early Passage and Senescent Vascular Endothelium is Modulated by VPF/VEGF: Evidence for Senescent Endothelial Cells In Vivo at Sites of Atherosclerosis,” The FASEB Jnl., 2001, 15: 458-466.
Lee Je-Ho
Lee Seung-Hoon
Crouch Deborah
Gates & Cooper LLP
Lieto Louis D.
LandOfFree
Method for using thymosin β-10 for gene therapy of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for using thymosin β-10 for gene therapy of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for using thymosin β-10 for gene therapy of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3627581